DAM
DSGN icon

DLD Asset Management’s Design Therapeutics DSGN Stock Holding History

DLD Asset Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,000
Closed -$377K – 406
2025
Q3 		$377K Buy
+50,000
New +$250K 0.03% 235

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

DLD Asset Management's DSGN Position: Q4 2025 in Review

DLD Asset Management sold out of Design Therapeutics (DSGN) in Q4 2025, closing a stake of 50,000 shares — an estimated $377K sold.

DLD Asset Management first reported a position in DSGN in Q3 2025 and held it in 1 quarter. The position peaked at $377K in Q3 2025. 117 funds tracked by Wall St. Rank hold DSGN as of Q4 2025.

  • DLD Asset Management reported no remaining Design Therapeutics position as of Q4 2025 after selling out during the quarter.
  • DLD Asset Management sold 50,000 Design Therapeutics shares in Q4 2025, an estimated $377K.
  • DLD Asset Management first reported a position in Design Therapeutics in Q3 2025 and held it in 1 quarter.
  • DLD Asset Management's Design Therapeutics position peaked at $377K in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2025.

Based on DLD Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.